Genetically engineered toxoplasma gondii p30 antigen, improved antigen cocktail and uses thereof
CA 2501040 C · Owner: Ginsburg, Sanford R. · Inventors: Patel, Chandu B.; Bliese, Timothy R.; Ginsburg, Sanford R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g. the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii. Furthermore the present invention also , relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens as well as kits and vaccines , containing the genetically engineered P30 antigen and antigens present in the combination.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 2, 2003 and granted April 21, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.